EUCTR2006-001141-34-DE进行中（未招募）不适用
Randomised, double-blind, double-dummy, cross-over trial comparing a novel DPI with formoterol versus Oxis Turbohaler 12 µg in patients with stable persistent asthma - Inhalatorstudie Formoterol DPI
ABOpoint GmbH0 个研究点开始时间: 2006年4月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All of the following criteria have to be met for inclusion of a subject in the study:
- •- men or women aged between 18 and 65 years
- •- written informed consent of patient
- •- current diagnosis of persistent asthma according to generally acknowledged criteria
- •- stable daily regimen of anti-inflammatory therapy (such as inhaled corticosteroids) upon at least 4 weeks
- •- a forced expiratory volume in one second (FEV1) between 40 and 90% of the predicted normal value
- •- documented FEV1-reversibility of at least 12%
- •- capable of understanding the directions for device usage
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are to be excluded from the study when one or more of the following conditions are met:
- •- respiratory tract infection less than 6 weeks prior to study entry
- •- acute asthma attack, which led to hospitalisation less than 1 month prior to study entry
- •- smokers less than 6 weeks prior to study entry
- •- medical history of cystic fibrosis or bronchiectasis
- •- systolic blood pressure more than 160 mm Hg, diastolic blood pressure more than 95mm Hg and heart rate > 100 bpm
- •- known hypersensitivity to formoterol or any of the ingredients of the study medication
- •- thyrotoxicosis, pheochromocytoma, idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, aneurysm or other severe cardiovascular disorders
- •- clinically significant conditions that might compromise patient safety, patient compliance, interfere with evaluations or preclude completion of the trial
- •- previous treatment within one month prior to the beginning of the study or concomitant treatment with substances which may decrease the efficacy of the test substance(s) or may lead to drug interactions, as for example: xanthine derivatives, diuretics, digitalis glycosides, antiarrhythmic agents like quinidine, disopyramide and procainamide, erythromycine, antihistamines with a potential for ventricular arrhythmias (i.e. terfenadine), tricyclic antidepressants, halogenated anaesthetics, beta-adrenergic blockers (including eye drops)
- •- abnormal 12-lead ECG at screening recorded after at least 5 min of rest in supine position
- •- prolonged QTc interval more than 460 ms for females and more than440 ms for males
- •- female patients: pregnancy or lactation
- •- history of alcohol and/or drug and/or substance abuse
- •- unwilling or unable to provide informed consent or to participate satisfactorily for the entire trial period
- •- current participation in another clinical study or former participation in this study
研究者
相似试验
进行中（未招募）
不适用
Randomised, double-blind, double-dummy, cross-over trial comparing salmeterol 50 µg b.i.d. via a novel DPI versus salmeterol 50 µg b.i.d. via Diskus in adult patients with persistent asthma - Inhalation Study Salmeterol DPIAdult patients with stable persistent asthmaMedDRA version: 9.1Level: LLTClassification code 10049106Term: Asthma chronicEUCTR2006-006793-26-DEmibe GmbH Arzneimittel
进行中（未招募）
不适用
Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parameters in the treatment of primary biliary cirrhosis - Ursofalk® tablets versus Ursofalk® capsules in the treatment of PBCEUCTR2008-001524-31-DEDr. Falk Pharma GmbH74
进行中（未招募）
1 期
Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parameters in the treatment of primary biliary cirrhosis - Ursofalk® tablets versus Ursofalk® capsules in the treatment of PBCTreatment of primary biliary cirrhosisMedDRA version: 9.1Level: LLTClassification code 10036680Term: Primary biliary cirrhosisEUCTR2008-001524-31-NLDr. Falk Pharma GmbH74
尚未招募
不适用
Comparative Study for the Compliance and Efficacy of Kynex and Kynex3 in Dry Eye PatientsDiseases of the eye and adnexaKCT0004912Gyeongsang National University Hospital60
已完成
不适用
A double-blind, randomised, double dummy, cross-over, study to assess the difference in efficacy between nebulisation of rhDNase in the morning versus nebulisation before going to sleepNutritional, Metabolic, EndocrineCystic fibrosisISRCTN74815264Roche Nederland BV (Netherlands)25